Business
PRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration Agreement
PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the "Collaboration") to develop an integrated, AI-navigated, physics-guided platform for the discovery of orally available small molecules targeting intracellular protein–protein interactions (PPIs), membrane proteins, and complex receptor systems.
About this update from Prism Biolab Co. Ltd
[{"type":"text","content":"— Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI —","length":135,"tagName":"p"},{"type":"text","content":"TOKYO, March 12, 2026 /PRNewswire/ -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the "Collaboration") to develop an integrated, AI-navigated, physics-guided platform for the discovery of orally available small molecules targeting intracellular protein–protein interactions (PPIs), membrane proteins, and complex receptor systems.","length":451,"tagName":"p"},{"type":"image","alt":"PRISM BioLab logo (PRNewsfoto/PRISM BioLab Co., Ltd.)","displaySize":"","headline":null,"caption":"PRISM BioLab logo (PRNewsfoto/PRISM BioLab Co., Ltd.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":99,"url":"https://media.zenfs.com/en/prnewswire.com/d67e964c5280408946c03686dc3c0d59"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xRzCw3pY3D9VEjtsSb.3IA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d67e964c5280408946c03686dc3c0d59","width":400,"height":99}},"href":"https://mma.prnewswire.com/media/2693058/PRISM_BioLab_logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Collaboration unites PRISM's PepMetics® chemistry — conformationally rigid, three-dimensional small molecules engineered to mimic α-helix and β-turn motifs — with Receptor.AI's physics-informed, multi-objective AI navigation engine. By integrating their technologies, the companies aim to generate innovative hit, lead and clinical candidate compounds against PPI and membrane-protein targets that have proven challenging for conventional small molecule drug discovery, with an initial focus on metabolic diseases, including obesity.","length":550,"tagName":"p"},{"type":"text","content":"The Collaboration will initially focus on one selected receptor target for metabolic disease. Receptor.AI will carry out molecular design using the combination of PRISM's chemical space and Receptor.AI's design algorithms. In parallel, the companies will jointly engage pharmaceutical partners interested in utilizing the combined capabilities of both technologies."...